A Retrospective, Cohort study to evaluate the role of the HLA-C*06:02 polymorphism during treatment with Adalimumab in patient with moderate-to-severe plaque psoriasis

Trial Profile

A Retrospective, Cohort study to evaluate the role of the HLA-C*06:02 polymorphism during treatment with Adalimumab in patient with moderate-to-severe plaque psoriasis

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2017 New trial record
    • 28 Jan 2017 Results published in the Molecular Diagnosis and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top